Security Snapshot

SINOVAC BIOTECH LTD. - Common Shares, par value US$0.001 per share (SVA) Institutional Ownership

CUSIP: P8696W104

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

8

Shares (Excl. Options)

6,270,749

Price

$6.47

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Shares, par value US$0.001 per share
Symbol
SVA on Nasdaq
Shares outstanding
71,872,133
Price per share
$6.47
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
6,270,749
Total reported value
$40,853,096
% of total 13F portfolios
0%
Share change
+7,439
Value change
+$329,323
Number of holders
8
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • SVA - SINOVAC BIOTECH LTD. - Common Shares, par value US$0.001 per share is tracked under CUSIP P8696W104.
  • 8 institutions reported positions in Q4 2025.
  • 6 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 8 to 1 between Q4 2025 and Q1 2026.
  • Reported value moved from $40,853,096 to $2,042,000.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 8 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP P8696W104?
CUSIP P8696W104 identifies SVA - SINOVAC BIOTECH LTD. - Common Shares, par value US$0.001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of SINOVAC BIOTECH LTD. - Common Shares, par value US$0.001 per share (SVA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
1Globe Capital LLC 32% 0% 18,515,315 0% 1Globe Capital LLC 07 Jul 2025
SAIF Partners IV L.P. 15% 0% 10,780,820 0% SAIF Partners IV L.P. 15 Dec 2025
WEIDONG YIN 8.8% 0% 6,359,500 0% Weidong Yin 10 Jul 2025
Advantech Capital L.P. 8.1% 0% 5,851,423 0% Advantech Capital L.P. 08 Jul 2025
Vivo Capital VIII, LLC 6.3% 0% 4,541,764 0% Vivo Capital IX, LLC 11 Jul 2025
Vivo Capital IX, LLC 6.3% $293,522,587 4,539,456 Vivo Capital IX, LLC 17 Mar 2025

As of 31 Dec 2025, 8 institutional investors reported holding 6,270,749 shares of SINOVAC BIOTECH LTD. - Common Shares, par value US$0.001 per share (SVA). This represents 8.7% of the company’s total 71,872,133 outstanding shares.

Institutional Holders of SINOVAC BIOTECH LTD. - Common Shares, par value US$0.001 per share (SVA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 315,586 $2,042,000 $6.47 1
2025 Q4 6,270,749 $40,853,096 +$329,323 $6.47 8
2025 Q3 8,982,045 $224,989,943 -$843,805 $6.47 8
2025 Q2 10,293,731 $375,364,173 +$39,325,578 $6.47 9
2025 Q1 3,034,321 $336,038,595 $64.66 2
2024 Q4 3,034,321 $336,038,595 -$76,346,336 $64.66 2
2024 Q3 14,834,373 $418,388,336 -$1,189,079 $6.47 4
2024 Q2 13,494,548 $79,577,415 -$1,059,870 $6.47 10
2024 Q1 12,345,841 $79,877,748 +$74,637,726 $6.47 11
2023 Q4 3,035,348 $345,241,022 -$39,640,820 $125.06 5
2023 Q3 6,591,632 $41,683,415 -$241,827 $6.47 14
2023 Q2 654,395 $4,040,321 +$1,998,321 $6.47 13
2023 Q1 8,934,321 $957,411,410 $104.30 3
2022 Q4 6,846,776 $44,307,000 -$2,179,000 $6.47 5
2022 Q3 6,549,095 $42,402,000 -$54,272 $6.47 15
2022 Q2 6,556,811 $43,219,000 +$1,612,000 $6.48 15
2022 Q1 6,307,855 $41,615,000 -$2,526,064 $6.47 6
2021 Q4 6,703,614 $43,337,796 +$45,098 $6.47 14
2021 Q3 6,692,031 $43,303,000 -$2,609 $6.47 14
2021 Q2 17,473,080 $448,658,000 -$10,419 $6.47 15
2021 Q1 6,694,343 $43,301,798 +$795,406 $6.47 14
2020 Q4 19,723,128 $113,774,000 -$4,542 $6.47 14
2020 Q3 6,567,108 $42,490,000 -$12,370 $6.47 13
2020 Q2 6,569,021 $42,502,000 -$443,106 $6.47 13
2020 Q1 9,476,962 $60,096,177 +$37,810,000 $6.47 16
2019 Q4 3,626,233 $22,285,000 +$420,812 $6.47 16
2019 Q3 5,943,883 $36,697,000 -$37,950,207 $6.47 14
2019 Q2 11,809,394 $74,647,000 -$363,749 $6.47 16
2019 Q1 11,866,163 $76,776,000 -$565,886 $6.47 20
2018 Q4 12,055,479 $83,665,328 -$1,526,233 $6.94 27
2018 Q3 12,261,649 $93,426,144 +$44,029,531 $7.62 27
2018 Q2 6,485,621 $48,379,952 -$2,603,545 $7.46 27
2018 Q1 6,825,579 $58,765,332 -$771,809 $8.61 27
2017 Q4 7,195,807 $56,704,456 -$4,237,018 $7.88 30
2017 Q3 18,130,684 $127,807,000 +$4,504,862 $7.04 34
2017 Q2 17,497,550 $118,106,000 -$9,432,662 $6.75 37
2017 Q1 18,903,143 $108,310,000 -$16,467,400 $5.73 35
2016 Q4 21,710,524 $128,091,000 -$2,317,439 $5.90 36
2016 Q3 11,345,665 $66,941,000 -$3,525,877 $5.90 36
2016 Q2 11,940,291 $70,803,000 -$984,267 $5.93 36
2016 Q1 12,095,339 $77,284,000 -$2,891,830 $6.39 34
2015 Q4 12,667,219 $72,454,000 -$2,035,397 $5.72 36
2015 Q3 13,170,988 $67,305,000 +$3,241,877 $5.08 34
2015 Q2 12,671,847 $66,523,675 +$330,944 $5.25 33
2015 Q1 12,615,535 $62,556,816 -$1,441,431 $4.96 37
2014 Q4 12,882,608 $67,344,058 -$771,710 $5.23 42
2014 Q3 12,951,642 $62,291,531 -$3,158,978 $4.81 43
2014 Q2 13,183,464 $74,347,660 -$7,915,266 $5.64 50
2014 Q1 14,476,121 $104,126,600 +$13,345,733 $7.20 51
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .